Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Generic drug approvals boost pharma firms' global ambitions

By Liu Zhihua | China Daily | Updated: 2019-03-07 11:42
Share
Share - WeChat
Many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. [Photo/VCG]

Chinese pharmaceutical companies are strengthening their presence on the world stage with an increasing number of generic drug approvals from the United States, thanks to rising research and development capabilities and official support for innovation, industry insiders said.

According to statistics from the Healthcare Executive Institute, a leading healthcare industry think tank based in Beijing, as of Dec 24, 2018, Chinese pharmaceutical companies had received 77 generic drug approvals - known as abbreviated new drug applications or ANDAs - from the US Food and Drug Administration.

The number was 38 in 2017 and 22 in 2016. Before 2016, Chinese pharmaceutical companies had fewer than 15 ANDAs approved on average each year.

A recent example is a generic drug made by Qingdao Baheal Pharmaceutical Ltd, a holding subsidiary of Baheal Pharmaceutical Group headquartered in Beijing and Qingdao, Shandong province.

Its generic drug Nida, which is an extended-release tablet containing metformin, a medicine widely used to manage type-2 diabetes, was approved by the USFDA on Dec 27, 2018.

The company announced earlier that the first batch of the drug was about to be delivered to the US market.

The think tank said one reason behind the rise in approvals is that many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. Another reason is that once a generic drug receives US approval, it is automatically seen as having passed China's generic consistency evaluation requirements.

In 2016, the Chinese central authorities issued an opinion on "conducting consistency evaluations of the quality and efficacy of generic drugs", signaling a push for an industrywide overhaul of generic drug quality. Failure to pass the evaluation before the required deadline leads to revocation of the drug title's registration license or ineligibility for government tendering. Besides, if three titles of a generic drug have passed the evaluation, others will not be allowed for government tendering.

Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy, added that the Chinese authorities' recent policies are very supportive of innovation and high-quality generic drug research and development, providing solid incentives for Chinese pharmaceutical companies to file more ANDAs.

"If a Chinese generic drug gains US approval, it is often fast tracked by Chinese authorities when it applies for domestic approval, giving it an advantage in the fiercely competitive domestic generic drug market," he said.

Shen Yaping, vice-president with Jiangsu Hengrui Medicine Co Ltd, a top Chinese pharmaceutical company listed in Shanghai, said the company now files new generic drug applications to domestic and US authorities for this reason.

"Going global and innovation are the two most important development strategies for our company, and now we feel encouraged, because a lot of government policies are inspiring to companies like us that want to expand overseas business," Shen said.

The overseas markets, especially the US, are large and alluring, yet in the past, Chinese pharmaceutical companies lacked the ability to expand overseas, he said, adding that as a number of first-tier Chinese pharmaceutical companies have succeeded in developing overseas business, others are trying to keep up with them.

His company and its subsidiary Shanghai Hengrui Pharmaceutical Co Ltd have received 16 ANDA approvals, according to its website.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 绿帽子巨物夺娇妻09| 孕交videodesexo孕交| 最近免费中文字幕大全免费版视频 | 日本免费xxxx色视频| 91免费福利视频| 男女xx动态图| 香蕉视频在线免费看| 贵州美女一级纯黄大片| 青青草国产成人久久91网| 胸大的姑娘动漫视频| 秋霞理论最新三级理论最| 男人j进入女人j内部免费网站| 男人天堂手机在线版| 欧美激情精品久久| 校花哭着扒开屁股浣肠漫画| 欧美a级毛欧美1级a大片免费播放| 日韩午夜激情视频| 成人亚洲欧美日韩在线观看| 岳又湿又紧粗又长进去好舒服| 天天操天天射天天| 国产精品VA在线播放| 国产亚洲精品美女2020久久| 台湾佬中文娱乐网在线更新| 伊人久久精品午夜| 亚洲av无码片在线观看| 久久96国产精品| 99热在线观看| 黄页免费视频播放在线播放| 翁与小莹浴室欢爱51章| 男人操女人的网站| 日韩高清免费观看| 思思91精品国产综合在线| 国产资源中文字幕| 国产乱人伦精品一区二区 | 娇妻校花欲乱往事叶子txt下载| 国产线视频精品免费观看视频| 国产成人免费av片在线观看| 免费看美女扒开腿让男人桶| 亚洲制服在线观看| 中文字幕看片在线a免费| 99re在线观看|